AU2001230447A1 - Male contraceptive formulation comprising norethisterone - Google Patents

Male contraceptive formulation comprising norethisterone

Info

Publication number
AU2001230447A1
AU2001230447A1 AU2001230447A AU3044701A AU2001230447A1 AU 2001230447 A1 AU2001230447 A1 AU 2001230447A1 AU 2001230447 A AU2001230447 A AU 2001230447A AU 3044701 A AU3044701 A AU 3044701A AU 2001230447 A1 AU2001230447 A1 AU 2001230447A1
Authority
AU
Australia
Prior art keywords
net
formulation according
androgen
testosterone
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001230447A
Other languages
English (en)
Inventor
Ursula-Friederike Habenicht
Axel Kamischke
Eberhard Nieschlag
Michael Oettel
Alexander Ruebig
Ekkerhard Schillinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU2001230447A1 publication Critical patent/AU2001230447A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2001230447A 2000-02-15 2001-02-15 Male contraceptive formulation comprising norethisterone Abandoned AU2001230447A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50372900A 2000-02-15 2000-02-15
EP00200493 2000-02-15
US09503729 2000-02-15
EP00200493 2000-02-15
PCT/IB2001/000188 WO2001060376A1 (en) 2000-02-15 2001-02-15 Male contraceptive formulation comprising norethisterone

Publications (1)

Publication Number Publication Date
AU2001230447A1 true AU2001230447A1 (en) 2001-08-27

Family

ID=26071832

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001230447A Abandoned AU2001230447A1 (en) 2000-02-15 2001-02-15 Male contraceptive formulation comprising norethisterone

Country Status (26)

Country Link
EP (2) EP1267885B8 (bs)
JP (1) JP2003522795A (bs)
KR (1) KR20020086905A (bs)
CN (1) CN1423560A (bs)
AT (2) ATE355844T1 (bs)
AU (1) AU2001230447A1 (bs)
BG (1) BG107066A (bs)
BR (1) BR0108411A (bs)
CA (1) CA2398063A1 (bs)
CY (1) CY1106639T1 (bs)
CZ (1) CZ20022691A3 (bs)
DE (2) DE60142647D1 (bs)
DK (1) DK1267885T3 (bs)
EE (1) EE200200454A (bs)
ES (1) ES2282230T3 (bs)
HK (1) HK1049442B (bs)
HU (1) HUP0300128A3 (bs)
IL (1) IL151219A0 (bs)
MX (1) MXPA02007675A (bs)
NO (1) NO20023607L (bs)
PL (1) PL357185A1 (bs)
PT (1) PT1267885E (bs)
RU (1) RU2002124602A (bs)
SI (1) SI1267885T1 (bs)
SK (1) SK11602002A3 (bs)
WO (1) WO2001060376A1 (bs)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10234525A1 (de) * 2002-07-25 2004-02-05 Schering Ag Zusammensetzung, enthaltend ein androgenes 11ß-Halogensteroid und ein Gestagen sowie männliches Kontrazeptivum auf Basis dieser Zusammensetzung
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
NZ537871A (en) 2002-07-24 2006-10-27 Schering Ag Microbiological processes for the production of 7 alpha-substituted 11 alpha-hydroxy steroids
DE50308933D1 (de) * 2002-07-25 2008-02-14 Bayer Schering Pharma Ag Zusammensetzung, enthaltend ein androgenes 11-b-halogensteroid und ein gestagen sowie m nnliches kontrazeptivum auf basis dieser zusammensetzung
CN101352443B (zh) * 2007-07-23 2011-01-12 中国科学院动物研究所 哺乳动物雄性不育剂
FI3750538T3 (fi) 2018-03-23 2024-09-24 Pharmajor Int (r)-silodosiinia käsittävät ei-hormonaaliset miesten ehkäisymenetelmät

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714420A1 (de) * 1976-06-01 1977-12-08 Int Pregnancy Advisory Service Antikonzeptionsmittel zur verabreichung an mann und frau in einer gemeinsamen verabreichungspackung
US4210644A (en) 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
CN1102095A (zh) * 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
DE19650352A1 (de) * 1996-12-04 1998-07-30 Jenapharm Gmbh Oral wirksames Kombinationspräparat zur Kontrazeption für den Mann

Also Published As

Publication number Publication date
NO20023607L (no) 2002-10-15
CZ20022691A3 (cs) 2003-01-15
KR20020086905A (ko) 2002-11-20
PT1267885E (pt) 2007-05-31
EP1267885B8 (en) 2007-06-20
SK11602002A3 (sk) 2003-03-04
DK1267885T3 (da) 2007-07-09
NO20023607D0 (no) 2002-07-30
ATE474580T1 (de) 2010-08-15
BR0108411A (pt) 2003-03-11
CN1423560A (zh) 2003-06-11
EP1267885A1 (en) 2003-01-02
DE60127103D1 (de) 2007-04-19
EP1666044B1 (en) 2010-07-21
ATE355844T1 (de) 2007-03-15
EP1267885B1 (en) 2007-03-07
MXPA02007675A (es) 2004-02-26
JP2003522795A (ja) 2003-07-29
PL357185A1 (en) 2004-07-26
HUP0300128A2 (en) 2003-05-28
WO2001060376A1 (en) 2001-08-23
HK1049442B (zh) 2007-06-15
EP1666044A1 (en) 2006-06-07
HK1049442A1 (en) 2003-05-16
HUP0300128A3 (en) 2004-03-29
CY1106639T1 (el) 2012-01-25
RU2002124602A (ru) 2004-03-10
EE200200454A (et) 2003-12-15
DE60142647D1 (de) 2010-09-02
IL151219A0 (en) 2003-04-10
ES2282230T3 (es) 2007-10-16
SI1267885T1 (sl) 2007-08-31
CA2398063A1 (en) 2001-08-23
BG107066A (en) 2003-05-30
DE60127103T2 (de) 2007-11-22

Similar Documents

Publication Publication Date Title
US20060142257A1 (en) Male contraceptive formulation comprising norethisterone
US7025979B2 (en) Male contraceptive formulation comprising norethisterone
US5891462A (en) Composition for transdermal administration of an estrogen
Swerdloff et al. Control of LH and FSH secretion in the male: evidence that aromatization of androgens to estradiol is not required for inhibition of gonadotropin secretion
EP1482925B1 (en) 5-(2-hydroxy-3-'1-(3-trifluoromethylphenyl)-cyclopropl]-propionylamino)-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy
DE60209907T2 (de) Verwendung von oestrogenverbindungen zur steigerung der libido bei frauen
US20040092494A9 (en) Method of increasing testosterone and related steroid concentrations in women
JPH04504848A (ja) エストロゲン感受性疾患の治療のための組合せ療法
EP1390041A1 (en) Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
EP1267885B1 (en) Male contraceptive formulation comprising norethisterone and testosterone undecanoate
US4181721A (en) Depot preparations in an oily, unsaturated solution for intramuscular injection
AU639467B2 (en) Compositions useful as contraceptives in males
GB1569286A (en) Oily depot solutions of gestagents for intramuscular injection
CN101332174A (zh) 二氢睾酮外用制剂及其药物用途
US7169769B2 (en) 17α-hydroxy-14β-steroids with hormonal effect
KR100481459B1 (ko) 에스트로겐,프로게스틴또는이의혼합물의경피투여용조성물
Lindsay et al. Oestrogenic and antioestrogenic activities of a number of steroids in behavioural oestrus and vaginal smear assays in the ewe
BIRCHALL et al. Effect of antihistamines on ribonucleic acid synthesis in the uterus of the ovariectomized rat
PL214858B1 (pl) Środek leczniczy na bazie noretysteronu lub jego farmaceutycznie dopuszczalnej pochodnej i estradiolu lub jego farmaceutycznie dopuszczalnej pochodnej